Paper Details

  1. Home
  2. Paper Details

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Author: , BaumhoerDaniel, BernsteinMark, BielackStefan S, BrennanBernadette, Butterfass-BahloulTrude, BöhlingTom, CalaminusGabriele, DeffenbaughClaudia, DhoogeCatharina, ErikssonMikael, GebhardtMark, GelderblomHans, GerssJoachim, GoorinAllen, GorlickRichard, HelmkeKnut, HogendoornPancras C W, HoogerbruggePeter M, HookJane M, JovicGordana, JürgensHeribert, KagerLeo, KrailoMark D, KühneThomas, LauChing C, LetsonG Douglas, MarinaNeyssa, MeyerJames, MeyersPaul, MichelagnoliMaria, MorrisCarol, NadelHelen, NagarajanRajaram, PictonSusan, PápaiZsuzsanna, RandallR Lor, ReichardtPeter, RenardMarleen, SchombergPaula, SeddonBeatrice, SmelandSigbjørn, Sundby HallKirsten, SydesMatthew R, TeotLisa A, TunnPer-Ulf, WernerMathias, WhelanJeremy S, WindhagerReinhard, van den BergHenk

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
WebcastA live or recorded video or audio broadcast distributed over the Internet.

Overview

MAP plus IFN-α-2b was not statistically different from MAP alone in treating osteosarcoma. A considerable proportion of patients never started IFN-α-2b or stopped prematurely.
Paper Details　
Original Abstract of the Article :
PURPOSE: EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy. PATIENTS AND METHODS: At diagnosis, patients age ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486345/

データ提供：米国国立医学図書館（NLM）

Methotrexate, Doxorubicin, and Cisplatin Plus Maintenance Pegylated Interferon Alfa-2b in Osteosarcoma

This study, part of the EURAMOS-1 trial, investigated the effectiveness of maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients with osteosarcoma who exhibited a good histologic response to induction chemotherapy. The researchers randomly assigned 716 patients to receive either four additional cycles of MAP (methotrexate, doxorubicin, and cisplatin) with or without IFN-α-2b. The primary outcome measure was event-free survival (EFS).

Maintenance Therapy for Osteosarcoma: A Complex Landscape

The study found that maintenance therapy with IFN-α-2b did not demonstrate a statistically significant improvement in EFS compared to MAP alone. A substantial number of patients either did not start IFN-α-2b or stopped prematurely due to factors like refusal or toxicity. The study highlights the challenges of implementing maintenance therapy in osteosarcoma, suggesting that further research is needed to identify optimal strategies for this patient population.

Navigating the Desert of Cancer Treatment

Navigating the desert of cancer treatment can be a complex and arduous journey. This study provides valuable insights into the challenges of implementing maintenance therapy for osteosarcoma. It emphasizes the need for careful consideration of factors such as patient preferences, toxicity profiles, and potential benefits when making treatment decisions. Just as a camel must choose its path carefully to avoid treacherous terrain, clinicians must navigate the landscape of treatment options with meticulous care to ensure the best possible outcomes for their patients.

Dr.Camel's Conclusion

This study provides valuable insights into the complexities of maintenance therapy in osteosarcoma. While the addition of IFN-α-2b to MAP did not demonstrate a significant improvement in EFS, the study highlights the challenges of implementing maintenance therapy in this patient population. Further research is needed to identify optimal strategies for maintenance therapy in osteosarcoma, taking into account factors such as patient preferences, toxicity profiles, and individual patient characteristics.

Date :
  1. Date Completed 2015-09-21
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

26033801

DOI: Digital Object Identifier

PMC4486345

Related Literature

Article Analysis
・Effects of peginterferon alfa-2b (peg-intron)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.